Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Relay Therapeutics Q2 EPS $(0.41) Beats $(0.48) Estimate, Sales $677.000K Beat $54.545K Estimate

Author: Benzinga Newsdesk | August 07, 2025 03:10pm
Relay Therapeutics (NASDAQ:RLAY) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.48) by 14.76 percent. This is a 40.58 percent increase over losses of $(0.69) per share from the same period last year. The company reported quarterly sales of $677.000 thousand which beat the analyst consensus estimate of $54.545 thousand by 1.14K percent.

Posted In: RLAY


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist